Rocket Pharmaceuticals Gestione

Gestione criteri di controllo 2/4

Rocket Pharmaceuticals Il CEO è Gaurav Shah, nominato in Jan2018, e ha un mandato di 6.83 anni. la retribuzione annua totale è $ 8.01M, composta da 7.8% di stipendio e 92.2% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 1.22% delle azioni della società, per un valore di € 14.87M. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 3.2 anni e 6.8 anni.

Informazioni chiave

Gaurav Shah

Amministratore delegato

US$8.0m

Compenso totale

Percentuale dello stipendio del CEO	7.8%
Mandato del CEO	6.8yrs
Proprietà del CEO	1.2%
Durata media del management	3.2yrs
Durata media del Consiglio di amministrazione	6.8yrs

Aggiornamenti recenti sulla gestione

Recent updates

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Gaurav Shah rispetto agli utili di Rocket Pharmaceuticals?
Data	Compenso totale	Stipendio	Guadagni aziendali
Sep 30 2024	n/a	n/a	-US$258m
Jun 30 2024	n/a	n/a	-US$253m
Mar 31 2024	n/a	n/a	-US$249m
Dec 31 2023	US$8m	US$625k	-US$246m
Sep 30 2023	n/a	n/a	-US$253m
Jun 30 2023	n/a	n/a	-US$249m
Mar 31 2023	n/a	n/a	-US$237m
Dec 31 2022	US$7m	US$598k	-US$222m
Sep 30 2022	n/a	n/a	-US$199m
Jun 30 2022	n/a	n/a	-US$192m
Mar 31 2022	n/a	n/a	-US$172m
Dec 31 2021	US$8m	US$590k	-US$169m
Sep 30 2021	n/a	n/a	-US$186m
Jun 30 2021	n/a	n/a	-US$165m
Mar 31 2021	n/a	n/a	-US$155m
Dec 31 2020	US$7m	US$540k	-US$140m
Sep 30 2020	n/a	n/a	-US$99m
Jun 30 2020	n/a	n/a	-US$89m
Mar 31 2020	n/a	n/a	-US$82m
Dec 31 2019	US$4m	US$480k	-US$77m
Sep 30 2019	n/a	n/a	-US$85m
Jun 30 2019	n/a	n/a	-US$82m
Mar 31 2019	n/a	n/a	-US$79m
Dec 31 2018	US$6m	US$414k	-US$75m

Compensazione vs Mercato: La retribuzione totale di Gaurav ($USD 8.01M ) è superiore alla media delle aziende di dimensioni simili nel mercato German ($USD 1.65M ).

Compensazione vs guadagni: La retribuzione di Gaurav è aumentata nonostante l'azienda non sia redditizia.

AMMINISTRATORE DELEGATO

Gaurav Shah (49 yo)

6.8yrs

Mandato

US$8,013,553

Compensazione

Dr. Gaurav D. Shah, M.D., has been an Independent Director at Talaris Therapeutics, Inc. since December 2020. He serves as the Chief Executive Officer and Director of Rocket Pharmaceuticals, Ltd since Janu...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Gaurav Shah	CEO & Director	6.8yrs	US$8.01m	1.22% € 14.9m
Kinnari Patel	Head of R&D	6.8yrs	US$4.85m	0.44% € 5.4m
Mayo Pujols	Chief Technical Officer	2.3yrs	US$4.38m	0.062% € 756.3k
Jonathan Schwartz	Chief Medical & Gene Therapy Officer	6.8yrs	US$3.16m	0.11% € 1.3m
Aaron Ondrey	Chief Financial Officer	less than a year	Nessun dato	Nessun dato
Martin Wilson	General Counsel	3yrs	US$1.56m	0.070% € 848.9k
Kevin Giordano	Director of Corporate Communications	no data	Nessun dato	Nessun dato
Isabel Carmona	Chief People Officer	3.2yrs	Nessun dato	Nessun dato
Gayatri Rao	Senior VP of Clinical Safety & Chief Regulatory Officer	4.6yrs	Nessun dato	Nessun dato
Raj Prabhakar	Chief Business Officer	no data	US$2.82m	0% € 0
Carlos Martin	Chief Commercial Operations & Revenue Officer	less than a year	Nessun dato	Nessun dato

3.2yrs

Durata media

49yo

Età media

Gestione esperta: Il team dirigenziale di 9IP1 è considerato esperto (durata media dell'incarico 3.2 anni).

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Gaurav Shah	CEO & Director	6.8yrs	US$8.01m	1.22% € 14.9m
David Southwell	Independent Director	10.3yrs	US$399.99k	0.13% € 1.5m
Pedro Granadillo	Independent Director	6.8yrs	US$429.98k	0% € 0
Carsten Boess	Independent Director	8.8yrs	US$427.49k	0% € 0
Mikael Dolsten	Independent Director	less than a year	Nessun dato	Nessun dato
Roderick Tze Wong	Chairman of the Board	6.8yrs	US$409.99k	0.059% € 716.1k
Naveen Yalamanchi	Independent Director	6.8yrs	US$417.49k	0.13% € 1.5m
Fady Malik	Independent Non-Executive Director	2.7yrs	US$399.99k	0% € 0
Elisabeth Bjork	Independent Director	4.6yrs	US$409.99k	0% € 0
Gotham Makker	Director	6.8yrs	US$399.99k	0.22% € 2.6m
Robert Woods	Independent Non- Executive Director	less than a year	US$568.70k	Nessun dato

6.8yrs

Durata media

58yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di 9IP1 sono considerati esperti (durata media dell'incarico 6.8 anni).

Rocket Pharmaceuticals Gestione

Gestione criteri di controllo 2/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Rocket Pharmaceuticals, Inc. Appoints Mikael Dolsten to the Board

Rocket Pharmaceuticals, Inc., Annual General Meeting, Jun 13, 2024

Insider recently sold €284k worth of stock

Rocket Pharmaceuticals, Inc. Announces Executive Appointments

CEO & Director recently sold €561k worth of stock

Rocket Pharmaceuticals, Inc. Appoints R. Keith Woods as Independent, Non-Executive Director

Recent updates

New minor risk - Profitability

Rocket Pharmaceuticals, Inc. Announces Completion of Enrollment in Phase 2 Pivotal Trial of RP-A501 for the Treatment of Danon Disease

Rocket Pharmaceuticals, Inc. Appoints Mikael Dolsten to the Board

Rocket Pharmaceuticals, Inc. Provides Regulatory Update on KRESLADI™ (marnetegragene autotemcel; marne-cel)

Rocket Pharmaceuticals Presents Positive Data from Lv Hematology Portfolio At the 27Th Annual Meeting of the American Society of Gene and Cell Therapy (Asgct)

New minor risk - Profitability

Rocket Pharmaceuticals, Inc., Annual General Meeting, Jun 13, 2024

Insider recently sold €284k worth of stock

Rocket Pharmaceuticals, Inc. Announces European Medicines Agency Acceptance of RP-L102 Marketing Authorization Application for the Treatment of Fanconi Anemia

Rocket Pharmaceuticals, Inc. Announces Executive Appointments

No longer forecast to breakeven

CEO & Director recently sold €561k worth of stock

Rocket Pharmaceuticals, Inc. Announces Update on Fda Review Timeline of Kresladi™ (Marnetegragene Autotemcel) for the Treatment of Severe Leukocyte Adhesion Deficiency-I (Lad-I)

New minor risk - Profitability

Forecast to breakeven in 2026

Rocket Pharmaceuticals, Inc. Appoints R. Keith Woods as Independent, Non-Executive Director

New major risk - Revenue and earnings growth

New minor risk - Profitability

Rocket Pharmaceuticals, Inc. Announces Fda Acceptance of Biologics License Application with Priority Review for Rp-L201 (Marnetegragene Autotemcel) for the Treatment of Severe Leukocyte Adhesion Deficiency-I (Lad-I)

Rocket Pharmaceuticals Receives European Medicines Agency (Ema) Priority Medicines (Prime) Designation for RP-A501 Gene Therapy for Danon Disease

CEO & Director recently sold €81k worth of stock

Rocket Pharmaceuticals, Inc. Announces FDA Clearance of IND for Clinical Trial of RP-A601 for PKP2 Arrhythmogenic Cardiomyopathy (ACM)

Insufficient new directors

Insider recently sold €64k worth of stock

Rocket Pharmaceuticals Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for RP-A501 Gene Therapy for Danon Disease

Rocket Pharmaceuticals Expands Cardiac Gene Therapy Portfolio with Addition of RP-A601 for PKP2-ACM

Rocket Pharmaceuticals, Inc. Provides Update on Anticipated Registration Path for RP-A501 in Danon Disease Following End-Of-Phase 1 FDA Meeting

Rocket Pharmaceuticals, Inc. (NasdaqGM:RCKT) completed the acquisition of Renovacor, Inc. (NYSEAM:RCOR) from RTW Investments, LP, Chardan Investments 2, LLC and others,

Rocket Pharmaceuticals, Inc. Announces Presentations Highlighting Lentiviral Gene Therapies at the 29th Annual Congress of the European Society of Gene & Cell Therapy (ESGCT)

Rocket Pharmaceuticals Announces Positive Updates from Phase 1 Clinical Trial for RP-A501 in Danon Disease at the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2022

Rocket Pharmaceuticals, Inc. (NasdaqGM:RCKT) entered into a definitive agreement to acquire Renovacor, Inc. (NYSEAM:RCOR) from RTW Investments, LP and others for $46.7 million.

Rocket Pharmaceuticals, Inc. (NasdaqGM:RCKT) entered into a definitive agreement to acquire Renovacor, Inc. (NYSEAM:RCOR) from RTW Investments, LP and others for $46.7 million.

Rocket Pharmaceuticals, Inc. Appoints Mayo Pujols as Chief Technical Officer and Executive Vice President

Rocket Pharmaceuticals Presents Positive Top-Line Data from Severe Leukocyte Adhesion Deficiency-I Program At the 25Th Annual Meeting of the American Society of Gene and Cell Therapy (Asgct)

Rocket Pharmaceuticals, Inc. Presents Positive Clinical Data from Danon Disease, Fanconi Anemia and Pyruvate Kinase Deficiency Programs at the 25th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT)

Rocket Pharmaceuticals, Inc., Annual General Meeting, Jun 13, 2022

Rocket Pharmaceuticals Appoints Fady Malik to Board of Directors

Rocket Pharmaceuticals Appoints Jessie Yeung as Vice President of Investor Relations and Corporate Finance

CEO & Director recently bought €334k worth of stock

Rocket Pharmaceuticals Presents Positive Clinical Data from Company’s Lentiviral Gene Therapies for Treatment of Fanconi Anemia, LAD-I and PKD at the 63rd American Society of Hematology (ASH) Annual Meeting

Rocket Pharmaceuticals, Inc. Presents Positive Clinical Data from Fanconi Anemia, Leukocyte Adhesion Deficiency-I, and Pyruvate Kinase Deficiency Programs at 24Th Annual Meeting of the American Society of Gene and Cell Therapy

Rocket Pharmaceuticals Receives FDA Regenerative Medicine Advanced Therapy Designation for RP-L201 Gene Therapy for Leukocyte Adhesion Deficiency-I

New 90-day high: €52.50

Rocket Pharmaceuticals, Inc. Announces Executive Appointments

Rocket Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $260.000048 million.

Rocket Pharmaceuticals Presents Positive Clinical Data from its Fanconi Anemia and Leukocyte Adhesion Deficiency-I Programs at the 62nd American Society of Hematology Annual Meeting

New 90-day high: €50.00

Rocket Pharmaceuticals Announces Positive Preliminary Clinical Data from Phase 1 Trial of RP-L301 for the Treatment of Pyruvate Kinase Deficiency at the 62nd American Society of Hematology Annual Meeting

New 90-day high: €28.40

Inotek Pharmaceuticals Corporation Receives Funding from the California Institute for Regenerative Medicine for Phase 1 Clinical Trial of RP-L401 for Infantile Malignant Osteopetrosis

Rocket Pharmaceuticals, Inc. Presents Positive LAD-L Clinical Update and Comprehensive IMO Preclinical Review At the European Society for Immunodeficiencies 2020 Meeting

New 90-day high: €25.00

New 90-day high - €22.40

Rocket Pharmaceuticals, Inc.(NasdaqGM:RCKT) dropped from Russell Microcap Index

Analisi delle retribuzioni degli amministratori delegati

AMMINISTRATORE DELEGATO

Mandato

Compensazione

Gruppo dirigente

Durata media

Età media

Membri del Consiglio di amministrazione

Durata media

Età media